COGNITION THERAPEUTICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $37.2M | $41.7M | $37.2M | $30.3M | $18.6M |
| Operating expenses | $47.8M | $54.0M | $50.7M | $43.6M | $28.6M |
| Operating income | -$47.8M | -$54.0M | -$50.7M | -$43.6M | -$28.6M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$23.5M | -$34.0M | -$25.8M | -$21.4M | -$11.7M |
| Balance Sheet | |||||
| Cash and equivalents | $36.8M | $25.0M | $29.9M | $41.6M | $54.7M |
| Current assets | $48.0M | $29.6M | $34.2M | $47.6M | $59.0M |
| Total assets | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M |
| Current liabilities | $13.9M | $11.1M | $10.2M | $7.8M | $7.9M |
| Total liabilities | $14.1M | $11.5M | $10.7M | $10.2M | $7.9M |
| Stockholders' equity | $34.3M | $18.8M | $24.5M | $40.2M | $51.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$24.6M | -$28.5M | -$16.0M | -$18.5M | -$3.6M |
| Depreciation and amortization | $36,000 | $107,000 | $96,000 | $83,000 | $93,000 |
| Stock-based compensation | $2.1M | $3.7M | $4.4M | $3.6M | $5.2M |
| Capital expenditure | — | $4,000 | $147,000 | $171,000 | $27,000 |
| Free cash flow | — | -$28.5M | -$16.2M | -$18.7M | -$3.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 89.5M · Free float 80.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.